Clinical trial NCT00875641: Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
Official title: Safety Study of GSK Biologicals' Rotarix® (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infections, Rotavirus
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2009-04-03
Enrollment: 390659
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children affiliated to two participating health insurance plans.

Brief summary: This observational cohort study, conducted through two existing large administrative health databases in the US (outside the Vaccine Safety Datalink) is planned to confirm the safety profile regarding lack of any association of intussusception with Rotarix within 60 days of vaccination in a real life setting (routine use) in the US. This study will also include monitoring of Kawasaki disease, convulsions, hospitalizations due to acute lower respiratory tract infections and all-cause deaths within 60-days of vaccination.

This study involves three cohorts, one exposed and two control cohorts: infants who receive Rotarix (Exposed cohort) and infants who receive IPV vaccination (Unexposed cohort A and B).

This is a combined prospective and retrospective cohort study. Prospective component of the study identifies and compares study outcomes following Rotarix and IPV vaccination in the Exposed cohort and Unexposed cohort A, respectively.

Retrospective component of the study identifies and compares study outcomes following IPV vaccination in the Unexposed cohort B.


Eligibility criteria: Inclusion Criteria:

For Exposed cohort:

* Infants aged less than 1 year at study entry.
* Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
* Have complete medical coverage and pharmacy benefits.
* Received at least one dose of Rotarix from 1 August 2008.
* Infants receiving Rotarix liquid formulation will also be eligible.

For Unexposed cohort A:

* Infants aged less than 1 year at study entry.
* Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
* Have complete medical coverage and pharmacy benefits.
* Received at least one dose of IPV vaccine from 1 August 2008, with or without RotaTeq vaccination.
* Frequency-matched to the Rotarix cohort by gender, age at first vaccination (±1 week) and calendar quarter of vaccination within the same year.

For Unexposed cohort B:

* Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
* Had complete medical coverage and pharmacy benefits.
* Received at least one dose of IPV vaccine.
* Vaccinated between 1 January 2006 (inclusive) and 31 July 2008 (inclusive).
* Not received any dose of rotavirus vaccination.
* Frequency-matched to the Rotarix cohort by gender, age at first vaccination (±1 week) and calendar quarter of vaccination.

Exclusion Criteria:

For Exposed cohort:

• Subject has received any dose of RotaTeq prior to the first Rotarix vaccine during the study period.

For Unexposed cohort A:

• Subject has received any dose of Rotarix prior to the first IPV vaccine during the study period.

For Unexposed cohort B:

• Subject has received any dose of rotavirus vaccines prior to the first IPV vaccine.

Primary outcomes:
measure: Incidence Rates of Intussusceptions (IS) Among the HRV Cohort and Comparator Cohorts
timeFrame: 60 days following each vaccination
measure: Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts
timeFrame: 7 days following each vaccination
measure: Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts
timeFrame: 30 days following each vaccination
Secondary outcomes:
measure: Incidence Rates of Kawasaki Disease Among the HRV Cohort and Comparator Cohorts
timeFrame: 60 days following each vaccination
measure: Incidence Rates of Convulsions Among the HRV Cohort and Comparator Cohorts
timeFrame: 60 days following each vaccination
measure: Incidence Rates of Acute Lower Respiratory Tract Infection (LRTI) Hospitalisation Among the HRV Cohort and Comparator Cohorts
timeFrame: 60 days following each vaccination
measure: Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts
timeFrame: 7 days following each vaccination
measure: Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts
timeFrame: 30 days following each vaccination
measure: Incidence Rates of All-cause Mortality Among the HRV Cohort and Comparator Cohorts
timeFrame: 60 days following each vaccination
Other outcomes:
Locations:
city: Waltham
country: United States
facility: GSK Investigational Site
state: Massachusetts
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: